Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting

Mental Health in Family Medicine

Volumn 9, Issue 3, 2012, Pages 137-148

  Ghate, Sameer R ^a   Porucznik, Christina A ^a   Said, Qayyim ^b   Hashibe, Mia ^a   Joy, Elizabeth ^a   Brixner, Diana I ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Adolescents; Antipsychotics; Guidelines; Metabolic monitoring; Primary care

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CORTICOSTEROID; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE MONITORING; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DEPRESSION; DIET RESTRICTION; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCHOOL CHILD;

EID: 84876168087     PISSN: 1756834X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161(2 Suppl):1-56.
2. National Institute for Health and Clinical Excellence. Bipolar Disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care: quick reference guide. National Institute for Health and Clinical Excellence: London, 2006.
3. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. Journal of Clinical Psychiatry 2010;71(Suppl E1):e04. DOI:10.4088/JCP.9058se1c.04gry
4. Olfson M, Blanco C, Liu L, Moreno C and Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006;63(6):679-85. DOI:63/6/679 [pii]10.1001/archpsyc.63.6.679
5. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.
6. US Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. In: FDA Safety News; Show#28, 2004. Available at: www.accessdata.fda.gov/psn/transcript.cfm?show=28 (accessed 08/02/11).
7. FDA USFaDA. Zyprexa (olanzapine): use in adolescents. 2010. Available at: www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsForHumanMedicalProducts/ucm198402.htm (accessed 03/11/2010).
8. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 2009;166(3):345-53. DOI:appi.ajp.2008. 08030383 [pii] 10.1176/appi.ajp.2008.08030383
9. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S and Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology 2009;29(1):26-32. DOI:10.1097/JCP.0b013e31819294cb00004714- 20090200
10. Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR and Rahnavard F. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Journal of the American Pharmaceutical Association 2003;48(3):393-400. DOI:N01234155308VG48 [pii] 10.1331/JAPhA.2008.07007
11. Morrato EH, Nicol GE, Maahs D et al. Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatric and Adolescent Medicine 2009;164(4):344-51. DOI:164/4/344 [pii] 10.1001/archpediatrics.2010.48
12. Brixner DI, Said Q, Corey-Lisle PK et al. Naturalistic impact of second-generation antipsychotics on weight gain. Annals of Pharmacotherapy 2006;40(4):626-32. DOI:aph.1G564 [pii]10.1345/aph.1G564
13. McAdam-Marx C, Bouchard J, Aagren M, Conner C and Brixner DI. Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. Clinical Therapy 2011;33(1):110-20. DOI:S0149-2918(11)00025-7 [pii] 10.1016/j.clinthera.2011.01. 018
14. LaFleur J, McAdam-Marx C, Alder SS et al. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. Journal of Bone and Mineral Metabolism 2011;29(2):193-200. DOI: 10.1007/s00774-010-0207-y
15. King G and Langche Z. Logistic regression in rare events. Political Analysis 2001;9:135-63.
16. RELOGIT: Rare Events Logistic Regression [computer program]. Version 1.1. Harvard University: Cambridge, MA, 1999.
17. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM and Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302(16):1765-73. DOI:302/16/1765 [pii] 10.1001/jama.2009.1549
18. Panagiotopoulos C, Ronsley R and Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Canadian Journal of Psychiatry 2009;54(11):743-9.
19. Morrato EH, Druss BG, Hartung DM et al. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety 2011;20(1):66-75. DOI:10.1002/pds.2062
20. Baker JL, Olsen LW, Sorensen TI. Childhood bodymass index and the risk of coronary heart disease in adulthood. New England Journal of Medicine 2007;357(23):2329-37. DOI:357/23/2329 [pii] 10.1056/NEJMoa072515
21. Bhargava SK, Sachdev HS, Fall CH et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. New England Journal of Medicine 2004;350(9):865-75. DOI:10.1056/NEJMoa035698 350/9/865 [pii]
22. Sinaiko AR, Donahue RP, Jacobs DR Jr and Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children 0 s Blood Pressure Study. Circulation 1999;99(11):1471-6. (Pubitemid 29140914)
23. Srinivasan SR, Myers L and Berenson GS. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study. Diabetes 2002;51(1):204-9. (Pubitemid 34517999)